Patents Assigned to Otsuka Pharmaceutical Co., Ltd.
  • Sunscreen composition
    Patent number: 10925813
    Abstract: The present invention provides a sunscreen composition comprising two or more oil-soluble ultraviolet absorbers and composite silicone particles having an average particle diameter of 10 ?m or less.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: February 23, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Masahiko Tanaka, Miyoko Ogihara, Junko Kako
  • QUINOLONE COMPOUND
    Publication number: 20210032207
    Abstract: The present invention provides a compound represented by the formula (T) wherein X is a hydrogen atom or a fluorine atom; R is a hydrogen atom or alkyl; R1 is (1) cyclopropyl optionally substituted by 1 to 3 halogen atoms or (2) phenyl optionally substituted by 1 to 3 halogen atoms; R2 is alkyl, alkoxy, haloalkoxy, a halogen atom, cyano, etc.; and R3 is 7-oxo-7,8-dihydro-1,8-naphthyridinyl, 3-pyridyl, etc., or a salt thereof. The compound of the present invention has excellent antimicrobial activity against Clostridium difficile and is useful for the prevention or treatment of intestinal infection such as Clostridium difficile-associated diarrhea.
    Type: Application
    Filed: October 19, 2020
    Publication date: February 4, 2021
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Mamuti ABUDUSAIMI, Fangguo YE, Jiangqin SUN, Hisashi MIYAMOTO, Jay-Fei CHENG, Daisuke OKA
  • Pharmaceutical solid preparation comprising benzazepines and production method thereof
    Patent number: 10905694
    Abstract: The subject invention provides a novel pharmaceutical solid preparation that has superior disintegration properties and excellent solubility, leading to sufficient absorbability of active ingredients through the gastrointestinal tract. The pharmaceutical solid preparation of the present invention comprises: (a) 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzoazepine and/or salt thereof; (b) hydroxypropylcellulose containing a hydroxypropoxyl group in an amount of 50% or greater; and (c) at least one member selected from the group consisting of carmellose, sodium carboxy methyl starch, crospovidone, and low substituted hydroxypropylcellulose with an average particle diameter of 30 to 70 ?m, and a 90% cumulative particle diameter of 100 to 200 ?m.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: February 2, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Shinsuke Nakagawa, Kai Suzuki, Tadashi Mukai
  • TABLET COMPRISING 7-[4-(4-BENZO[B]THIOPHEN-4-YL-PIPERAZIN-1-YL)BUTOXY]-1H-QUINOLIN-2-ONE OR A SALT THEREOF
    Publication number: 20210023078
    Abstract: This invention relates to a tablet containing, as an active ingredient, 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, that has excellent disintegration ability, storage stability and photostability. The tablet of the present invention comprising an uncoated tablet containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, excipients such as lactose, corn starch, and microcrystalline cellulose; disintegrants such as low-substituted hydroxypropylcellulose, croscarmellose sodium, and sodium carboxymethyl starch; binders such as hydroxypropylcellulose; lubricants such as stearate; and further comprising a coating layer containing hypromellose; talc; titanium oxide; colorant; and the like, the coating layer being applied to the surface of the uncoated tablet.
    Type: Application
    Filed: October 1, 2020
    Publication date: January 28, 2021
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Yoshiharu INOUE
  • 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER
    Publication number: 20210017134
    Abstract: The present invention provides a novel compound having an excellent antitumor effect, stability and metabolic stability. The compound of the present invention is represented by the following general formula (1) wherein R1 represents a halogen atom, an aryl group, an aryloxy group or a lower alkyl group optionally substituted with one or more halogen atoms; R2 represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; and; m represents an integer of 1 to 3; provided that when m represents 2 or 3, R1s are the same or different.
    Type: Application
    Filed: September 30, 2020
    Publication date: January 21, 2021
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Takashi NAKAGAWA, Makoto SAKAMOTO, Kazuya YAMAGUCHI, Yuki TERAUCHI, Masamichi SHIRAKURA, Yasuo HARADA, Yutaka KOJIMA, Takumi SUMIDA
  • Benzazepine derivatives
    Patent number: 10889570
    Abstract: The present invention provides novel benzazepine compounds of Formula (1), or salts thereof, having vasopressin V1a and V2 antagonisms, and medical uses thereof. In the formula, R1 is optionally substituted C1-6 alkyl, etc.; L is —C(?O)—NH—, etc.; Ring A1 is a hydrocarbon ring, etc.; Ring A2 is a hydrocarbon ring, etc.; and each of Rings A1 and A2 may have at least one substituent.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: January 12, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Keizo Kan, Masatoshi Takuwa, Hirotaka Tanaka, Hideto Fujiwara, Hokuto Yamabe, Satoshi Matsuda, Kazuhiro Ohdachi, Taiki Hanari, Yasuhiro Menjo, Tatsuya Urushima, Shigekazu Fujita
  • FROZEN DESSERT COMPOSITION
    Publication number: 20200404944
    Abstract: The disclosure provides a frozen dessert composition comprising (A) about 6 to 15% by weight of palatinose based on the total weight of the composition, and (B) about 10 to 30% by weight of a dextrin or a combination of a dextrin and a soluble dietary fiber based on the total weight of the composition. The disclosure also provides a method of manufacturing a frozen dessert composition comprising mixing the following components with water; (A) about 6 to 15% by weight of palatinose based on the total weight of the composition, and (B) about 10 to 30% by weight of a dextrin or a combination of a dextrin and a soluble dietary fiber based on the total weight of the composition.
    Type: Application
    Filed: February 27, 2019
    Publication date: December 31, 2020
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Shogo MOCHIZUKI, Takashi SATO, Hiroshi HASEGAWA
  • INDUSTRIAL PROCESS OF MONO-ALKYLATING PIPERIDINE NITROGEN IN PIPERIDINE DERIVATIVE WITH DEUTERATED-LOWER-ALKYL
    Publication number: 20200407326
    Abstract: The present invention relates to a method of mono-alkylating a piperidine nitrogen in a piperidine derivative with a deuterated lower-alkyl, which comprises protecting the piperidine nitrogen with an aralkyl protective group, lower-alkylating the piperidine nitrogen with a deuterated-lower-alkylating agent under neutral or basic condition, and then deprotecting the aralkyl protective group.
    Type: Application
    Filed: September 6, 2018
    Publication date: December 31, 2020
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Yuya NAKAI, Masashi HAYASHI, Wataru MITSUHASHI
  • METHOD OF TREATING BIPOLAR I AND II DISORDERS
    Publication number: 20200405712
    Abstract: The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1) wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.
    Type: Application
    Filed: September 15, 2020
    Publication date: December 31, 2020
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Shaun Jordan, Tetsuro Kikuchi, Katsura Tottori, Tsuyoshi Hirose, Yasufumi Uwahodo
  • PYRIMIDINE COMPOUND
    Publication number: 20200399245
    Abstract: The present invention provides a novel pyrimidine compound represented by Formula [I] and a salt thereof: [in the formula, the symbols are as defined in the specification], which is useful for treating, preventing and/or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.
    Type: Application
    Filed: September 2, 2020
    Publication date: December 24, 2020
    Applicant: OTSUKA PHARMACEUTICAL CO, LTD.
    Inventors: Tomoichi SHINOHARA, Shin IWATA, Kenta ARAI, Nobuaki ITO, Masaki SUZUKI
  • Drug compound and purification methods thereof
    Patent number: 10858386
    Abstract: The invention provides a method of preparing a lyophilized pharmaceutical composition containing a compound described herein or a pharmaceutically-acceptable salt thereof. The process comprises dissolving the compound in a solvent comprising dimethylsulfoxide and optionally one or more co-solvents to form a solution, and then removing the solvent and any co-solvents by a freeze-drying process. Also provided by the invention are lyophilized pharmaceutical compositions and their use in medicine and in particular in the treatment of cancer.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: December 8, 2020
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Rajashree Joshi-Hangal, Nipun Davar, Stephen R. Priebe
  • METHOD FOR SUPPRESSING DISCOLORATION OF EXTERNAL COMPOSITION CONTAINING ADENOSINE PHOSPHATE AND TRANEXAMIC ACID
    Publication number: 20200375867
    Abstract: The present disclosure provides a composition for external use comprising an adenosine phosphate and/or a salt thereof and tranexamic acid and/or a salt thereof, which further comprises a particular chelating agent and/or a pH adjuster that is an organic alkali compound.
    Type: Application
    Filed: January 30, 2019
    Publication date: December 3, 2020
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Miyoko OGIHARA, Momoko SUMA, Shiori MIYAWAKI
  • METHOD OF DETECTING MINOR BCR-ABL1 GENE
    Publication number: 20200377928
    Abstract: The disclosure provides a method comprising (1) conducting a PCR using a nucleic acid sample obtained from the subject as the template, a forward primer having a nucleic acid sequence of a part of exon 1 of the BCR gene, and a reverse primer having a nucleic acid sequence complementary to a part of exons 2 to 11 of the ABL1 gene, in the presence of a modified nucleic acid having a nucleic acid sequence of a part of exons 2 to 14 of the BCR gene or a nucleic acid sequence complementary thereto; and (2) determining that the subject has the minor BCR-ABL1 gene when the nucleic acid amplification is occurred in the PCR.
    Type: Application
    Filed: April 25, 2018
    Publication date: December 3, 2020
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Kiyonori KATSURAGI, Hideaki TANAKA, Ryuta ITO, Daisuke KOGA
  • Piperidine derivative
    Patent number: 10851079
    Abstract: The purpose of the present invention is to provide a compound having excellent antibacterial activity against mycobacterium tuberculosis, multidrug-resistant tuberculosis bacteria, and/or non-tuberculous acid-fast bacteria. A compound represented by formula [I]: (in the formula, each symbol is as described in the attached specification), or a salt thereof can be used to diagnose, prevent, and/or treat tuberculosis.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: December 1, 2020
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Yoshikazu Kawano, Hiroshi Shimizu, Shunpei Ishikawa, Isao Takemura, Norimitsu Hariguchi, Miki Matsuba, Makoto Matsumoto
  • COMBINATION OF BREXPIPRAZOLE AND NALMEFENE AND USE THEREOF FOR TREATING SUBSTANCE-RELATED DISORDERS
    Publication number: 20200368227
    Abstract: A medicament comprising (I) brexpiprazole or a pharmaceutically acceptable salt thereof, and (II) nalmefene or a pharmaceutically acceptable salt thereof in combination, wherein brexpiprazole or a pharmaceutically acceptable salt thereof, and nalmefene or a pharmaceutically acceptable salt thereof are contained in a single preparation, or a pharmaceutical composition containing brexpiprazole or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing nalmefene or a pharmaceutically acceptable salt thereof are formulated for use in combination. The medicament is used for the prophylaxis or treatment of a substance-related disorder, preferably an alcohol-related disorder.
    Type: Application
    Filed: August 13, 2020
    Publication date: November 26, 2020
    Applicants: OTSUKA PHARMACEUTICAL CO., LTD., H. LUNDBECK A/S
    Inventors: Kenji MAEDA, Mai NAKAMURA
  • METHOD OF PROVIDING ARIPIPRAZOLE TO PATIENTS HAVING IMPAIRED CYP2D6 OR CYP3A4 ENZYME FUNCTION
    Publication number: 20200360370
    Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
    Type: Application
    Filed: December 11, 2019
    Publication date: November 19, 2020
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventor: Arash Raoufinia
  • METHOD FOR ACTIVATING HELPER T CELL
    Publication number: 20200354405
    Abstract: The present invention relates to a method for activating helper T cells, which includes the step of activating helper T cells by adding a WT1 peptide to antigen presenting cells, wherein the WT1 peptide has the ability to bind to any MHC class II molecule of an HLA-DRB1*0101 molecule, an HLA-DRB1*0401 molecule, an HLA-DRB1*0403 molecule, an HLA-DRB1*0406 molecule, an HLA-DRB1*0803 molecule, an HLA-DRB1*0901 molecule, an HLA-DRB1*1101 molecule, an HLA-DRB3*0202 molecule, an HLA-DRB4*0101 molecule, an HLA-DPB1*0201 molecule or an HLA-DPB1*0301 molecule, and the like.
    Type: Application
    Filed: March 31, 2020
    Publication date: November 12, 2020
    Applicants: International Institute of Cancer Immunology, Inc., OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Haruo SUGIYAMA, Shinji SOGO, Masayoshi SATO, Ryuki KITAMOTO, Yoshihiro GOTO
  • KAEMPFEROL ANALOG-CONTAINING COMPOSITION
    Publication number: 20200323816
    Abstract: The present application provides a composition for improvement in physical activity efficiency, a composition for reducing fatigue, and a composition for improving dynamic/kinetic visual acuity, comprising a kaempferol analog.
    Type: Application
    Filed: August 30, 2018
    Publication date: October 15, 2020
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Yasutaka IKEDA, tsubasa MIZOKAMI, Yasuhiro ABIRU, Minoru AKIYAMA, Ayuko OYAMA
  • Pyrimidine compound
    Patent number: 10800758
    Abstract: The present invention provides a novel pyrimidine compound represented by Formula [I] and a salt thereof: [in the formula, the symbols are as defined in the specification], which is useful for treating, preventing and/or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: October 13, 2020
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tomoichi Shinohara, Shin Iwata, Kenta Arai, Nobuaki Ito, Masaki Suzuki
  • HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE
    Publication number: 20200281951
    Abstract: A heterocyclic compound represented by the general formula (1) or a salt thereof: wherein m, l, and n respectively represent an integer of 1 or 2; X represents —O— or —CH2—; R1 represents hydrogen, a lower alkyl group, a hydroxy-lower alkyl group, a protecting group, or a tri-lower alkylsilyloxy-lower alkyl group; R2 and R3, which are the same or different, each independently represent hydrogen or a lower alkyl group; or R2 and R3 are bonded to form a cyclo-C3-C8 alkyl group; and R4 represents an aromatic group or a heterocyclic group, wherein the aromatic or heterocyclic group may have one or more arbitrary substituent(s).
    Type: Application
    Filed: March 16, 2020
    Publication date: September 10, 2020
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Nobuaki ITO, Hirofumi SASAKI, Kuninori TAI, Tomoichi SHINOHARA